Cogentus Pharmaceuticals
Menlo Park
About Cogentus Pharmaceuticals
Cogentus Pharmaceuticals, Inc., a pharmaceutical company, develops prescription pharmaceutical products in North America and Europe. It develops CGT-2168, an oral formulation that combines clopidogrel with a gastroprotectant, which reduces the gastrointestinal side effects associated with dual antiplatelet therapy. The company was founded in 2006 and is based in Menlo Park, California. On January 16, 2009, Cogentus Pharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $77.5M
- Funding stage: Late Stage Venture
- Last round: Series C (Dec 2007)
- Website: cogentus.net
- Phone: 650-543-4730
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/cogentus-pharmaceuticals-2742716 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.